Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?

The phase III HELEN-006 trial of abraxane/trastuzumab/pertuzumab (AHP) vs TCHP was first presented with positive results at SABCS 2023, then at AACR 2024, and finally published fully in January 2025 in the Lancet. To summarize the findings, the Lancet 2025 article documented that in this randomized ...

Agree with considering patients with advanced age and co-morbidity while waiting for the long-term survival data.